NCT06900218 2025-04-02
PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
Clinical Trials
4 trialsNCT04557020 2024-05-01
Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC
Jiangxi Provincial Cancer Hospital
Phase 3 Unknown
NCT05342792 2022-04-25
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT04778956 2021-03-04
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting